Post on 17-Jan-2017
A Global Animal Health Company
Company OverviewOctober 2016
Pacific GeneTech Limited
C O N F I D E N T I A L
C O N F I D E N T I A L
PGT is a commercial stage company applying novel vaccine technologies against multiple diseases Cross-protective vaccines using highly conserved / broad spectrum antigens Orally administrable, eliciting IgA, IgG and T-cell responses Low cost manufacture & vaccine administration Viable alternatives to antibiotics
CompanyFounded in 2009 to commercialize discovery research from leading US Universities Experienced management, top-tier scientific advisors and a global network of R&D collaboratorsOffices in Hong Kong, U.S and Taiwan
ProductsOur technology platforms are covered by 10 patent families- The “Aegis” Recombinant Vaccine Platform- Two Adjuvant / Delivery Systems (“Hercules” & “Javelin”)
Pipeline
Hercules (mannosylated chitosan) is in the market in SE Asia in a novel oral H5N1 vaccine8 vaccine candidates:- 1 registration stage vaccine (Salmonella / Campylobacter for poultry)- 1 pre-registration stage vaccine (Eimeria for poultry)- 2 development stage vaccines (swine Salmonella / E. coli, influenza in poultry & swine)- 4 POC stage (Toxoplasma in mammals, Vibrio & Edwardsiella in fish, Necrotic Enteritis in
poultry, E. coli / EHEC in cows)Javelin (antibody guided antigen adjuvant / delivery system is in the development stage
FocusUnmet or under-served needs in animal health, including food safety & zoonotic diseasese.g. multiple GI Tract Diseases (Bacteria, Parasites) and Influenza
Financials Completed 4 rounds of funding with plans for a public offering in late 2016 / early 2017
Sources: (1) Future Market Insights, Veterinary Vaccines Market, 2016-2026;
2
Introduction to Pacific GeneTech
BY SPECIES
PoultrySwineRuminantsFish
CatsDogs
Our VisionTo Build The World’s Leading Company In 5th Gen Veterinary Vaccines
Current
Future
BY GEOGRAPHY
North America
Asia
Europe
Latin America
Middle East
Africa
Current
Future
BY PRODUCT & TECHNOLOGY
Recombinant
vaccines
Novel Adjuvants
& Delivery Systems
Synthetic
vaccines
Current
Future
PGT uses current, rapid innovation in genetics, molecular biology, immunology and bio-informatics to design cross-protective, low cost vaccines
CROSS-PROTECTION: A MAJOR GAME-CHANGER
3C O N F I D E N T I A L
Both live and killed Aegis vaccines can be administered orally
Oral administration has critical cost benefits with large numbers of animals – e.g. poultry
4
PGT’s Cross-protective, Orally Administrable, Low Cost Vaccines
Salmonella / Campylobacter vaccine is cross-protective against S Typhimurium, Heidelberg, Kentucky, Enteritidis; and E. coli, including a virulent EHEC strain
Eimeria vaccine is cross protective against 5 economically important species of Eimeria; andToxoplasma gondii (a related Apicomplexan parasite)
Cross ProtectionAcross multiple strains and even different species of pathogen
Oral Administration
All PGT’s inactivated Aegis vaccines use the Hercules adjuvant / delivery system Hercules promotes secretory IgA in mucous membranes, preventing pathogen invasion
C O N F I D E N T I A L
CONFIDENTIAL
lP Rights
Management
Ind. Knowledge
Investment
PGTDiscovery
Research Universities Research Institutes Companies
Market Channels Out licensees JV/Marketing Partners Direct Sales (B2B)
RevenuesPGT’s revenue streams
License fees, R&D payments, royalties
Direct Sales (Business to Business)
• PGT injects commercial / industry expertise taking discovery ideas through to market
• PGT identifies novel technologies for "first in class” / “best in class” products
In addition to license fee & royalty revenues, PGT generates sales revenues for Hercules
Active PGT Management
Active PGT Management
5
Our Business Model
CONFIDENTIAL
Executive
Chairman
Louis Bowen
• Investment banking, PE/VC industry in Asia since 1970s
• Overseen over 50 investments and acquisitions including companies in the life sciences fields
• Chairman of Asia Capital Management and was a co-founder of the Hong Kong Venture Capital Association
Leadership Team
CEO
Tim Collard
• > 40 years experience in the vaccine, biotechnology and pharmaceutical industries in Asia since the mid-1970s
• Experience MNCs (Squibb, Solvay, Porton) and entrepreneurial companies
• Biology at Bristol University (U.K)
Management Team
Director,
Business
Development
Cindy Tsang
• > 13 years of experience in pharma, investment banking and start-up industries
• Abbott Laboratories, Ernst & Young, Morgan Stanley
• M.B.A from University of Cambridge (U.K), BS Biochemistry from Seattle Univ (U.S)
Director, US
Operations
Dr. Tom
Overbay
• > 25 years of experience in the veterinary pharmaceutical industry
• Founder of Expedite Animal Health
• DVM from the Virginia-Maryland Regional College of Veterinary Medicine
Director,
Translational
Research
Dr. Anna
Obolensky
• > 40 years experience in pharmaceutical industry, research institutions and private equity
• Ph.D in Immunology at Keble College, Oxford
• Fellow of the Royal Society of Medicine/ Member of British Society of Immunology
Director,
R&D
(Taiwan)
Dr. Yahui
Huang
• > 15 years of research experience in academic and industry, regulatory process , technology transfer
• Qualified veterinarian• Ph.D in Biology from
University of Bath (U.K), MS/BS in Veterinary Medicine from National Taiwan Univ.
Director,
Commercial
Projects
Dr. Ariane
Davison
• Experience in the global biotech, healthcare equity and start-up industries
• Ph.D in Viral Immunology from the University of Sydney School of Medicine, and Honors in Molecular Genetics.
Scientific Advisors
Scientific
Advisor (US)
Dr. Billy Hargis
• Leads the University’s vaccine research team
• Research Director of the Poultry Health Laboratory (PHL) at the University of Arkansas
• D.V.M and Ph.D. training at the Univ of Minnesota
Scientific
Advisor (US)
Dr. Lisa Bielke
• Assistant Professor, Department of Animal Sciences, OARDC, Ohio State University
• Ph.D in Poultry Science at the University of Arkansas
• Board of Trustees for the Poultry Science Association Foundation
Our Leadership & Management Structure
6
Scientific
Advisor
Dr. Steve Chu
• > 30 years of experience in veterinary vaccine R&D
• Senior research positons with Ceva, Elanco, Fort Dodge.
• Ph.D in Microbiology from UC Davis, MS/DVM from National Taiwan Univ.
TaiwanGuangzhou
AustraliaNew Zealand
Indonesia
Thailand
Oxford
Edinburgh
Rhode Island
Ontario
GeorgiaTexasArkansas
Ohio
CONFIDENTIAL7
U of Arkansas
Lead-inventor, Aegis, Hercules.
Salmonella, Campy, Eimeria,
Avian Influenza research (poultry)
Texas A&M
Co-inventor of Aegis, Javelin.
Javelin development
Guelph U, Ontario
Co-inventor of Aegis, Eimeria
research (poultry)
Kansas State U, KS
E coli / EHEC (in-vitro model)
Vaccines Adjuvant / Delivery Systems
Pingtung U, Taiwan
E coli, Toxoplasma (mouse
model), Salmonella (pigs),
Vibrio & Edwardsiella (fish)
Chung Hsing U, Taiwan
Eimeria (poultry)
Zhong Shan U, China
Fish vaccine research
Medion, Indonesia
Avian Influenza
AFRIMS (Walter Reed),
Thailand
E coli & Salmonella
(mouse model)
Gamma Vaccines,
Australia
RBC, New Zealand
Toxoplasma & Neospora
(sheep)
Oxford
Hercules mode of
action research
Edinburgh U
Moredun / Roslin Inst.
E coli / EHEC (cows)
USDA, GA
Avian Influenza
research (poultry)
Epivax, RI
Toxoplasma mode of
action research
Ohio State UCo-inventor of Aegis.
Eimeria & Necrotic
Enteritis research
(poultry)
N America
Europe Asia/PacificA
Taiwan/China
V
V
V
A
A
A
A
A
V
V
V
V
V
A
A
A
V
V
V
Stirling U
Fish vaccine research
V
Kansas
A Growing Global Network of R&D Collaborators
Provisional Application
US Utility Application
PCT National Filings
Vaccines
1. Universal flu epitopes + CD154 (I.E.)
2. Eimeria TRAP epitope
3. fliC epitope for Enterobacteriaceae
4. Bacillus vectored HMGB1 (I.E.)
5. Campylobacter epitope + I.E. domains
6. PAL epitope for Enterobacteriaceae In process
7. Eimeria MPP epitope In process
8. Yeast Vector In process
Adjuvant / Delivery Systems
9. Hercules Modified Chitosan Adjuvant (MCA) In process
10. Javelin Antibody-guided Antigen (AgA)
8 Aegis Vaccine Patents filed globally + 2 Adjuvant / Delivery System Patents
Many of the above patents have been issued in multiple territoriesC O N F I D E N T I A L
PGT’s Patent Status
8
Salmonella +Campylobacter
Eimeria
Influenza
Salmonella & E. coli
Influenza
E coli (ETEC / EHEC)
ToxoplasmaCryptosporidium
Neospora
EdwardsiellaVibrio
Toxoplasma
Cross-protection Creates Synergies: Same Antigen Packages, Multiple Diseases
Poultry Swine Ruminants Fish Others
C O N F I D E N T I A L
3 vaccine families with broad cross-protection across multiple pathogen families in multiple animals
Red: GIT Bacteria Blue: Parasites Green: Viruses
9
Our Existing Aegis Vaccine Candidates
C O N F I D E N T I A L
Adjuvants / Delivery Systems
PGT Hercules (modified chitosan)
AvianInfluenza and
others
PGT Javelin (vaccine delivery system)
Avianinfluenza
Animal Vaccine Program
Food Safety/Enteric DiseaseSalmonella & Campylobacter
avian
Eimeriaavian
Food Safety/Enteric Disease (E. coli/EHEC)
ruminant
Food Safety/Enteric DiseaseSalmonella & E. coli
swine
Avian Influenza avian
Toxoplasmosisfeline &
ruminants
Necrotic Enteritis avian
Edwardsiella/Vibrosis fish
Launched in Q3 2016 in an oral H5N1 vaccine
Anticipated launch in 2017
USDA SIF filing Q2 2016; anticipate launch in 2018
Out-licensing opportunity for S. Amer. in Q4 2016 and N. Amer. in Q1 2017; US regulatory filing in 2017; Anticipated first launch in 2019
Discovery Research
Proof of Concept
DevelopmentRegulatory
ProcessMarket
Seeking partners & out-licensing opportunities
POC animal studies in progress
Seeking partners & out-licensing opportunities
Seeking partners & out-licensing opportunities
10
Our Pipeline Status – Multiple Value Drivers
POC animal studies in progress
C O N F I D E N T I A L
Aegis: A Breakthrough, Potentially Disruptive Recombinant Vaccine Platform
COOHNH2
Vector Cell Membrane
Inside of the cell
Conserved Epitope (Antigen)
Immune Potentiator e.g., HMGB1, CD40L
• Conserved antigens alone = poor protection
• Conserved antigens + immuno-potentiators = solid protection
11
PGT’s Patented Vaccine Technologies: Aegis, Hercules & Javelin
Hercules:
Mannosylated Chitosan adjuvant / delivery system is “sticky” – it passively adheres to mucous membranes and Antigen Presenting Cells in mucous membranes
Javelin:
Is guided to target by an antibody and actively adheres to CD40 on APCs
PGT is a commercial stage animal health biotech focused on:
Novel / breakthrough vaccine technologies
Unmet or under-served needs
Zoonotic diseases
Seeks partners for:
Out-licensing our vaccine technologies to suitable MNC and national-level commercial partners
In-licensing additional novel vaccine technologies
Research Collaborations
PGT has an attractive business model and is well positioned for an IPO:
We are planning a public offering in Taiwan; and
Raising a pre-IPO funding round
CONFIDENTIAL12
Investment Summary
CONFIDENTIAL
Appendix 1: How the Technology Works
14
• Developed using recombinant genetics• Platform incorporates combinations of key immuno-potentiating molecules e.g., CD40L, HMGB1
• Cloned with antigen sequences highly conserved between pathogens e.g., Salmonella, E.coli, Influenza
• The immuno-potentiators stimulate inflammatory cascades/cells and trigger immune responses• The vaccine construct specifically stimulates pathogen-specific immune responses
CONFIDENTIAL
A Breakthrough/Disruptive Recombinant Vaccine Platform:
COOHNH2
Vector Cell Membrane
Loop 1 9
2
Inside of the cell
Conserved Epitope (Antigen)
Immune Potentiator e.g., CD40L (multiple copies)
References: 1. Foodborne Path. and Disease, 2014, 11(2):165-169. 2. Int. J. Biotech. and Bioeng. Res. 2013, 4(6):589-596. 3. Clin. Vaccine Immunol., 2011, 18(3) 449-454. 4. Int. J. Poultry Science 2010, 9(11):1031-0137. 5. Poultry Science, 2010, 89:1399–1405. 6. Poultry Science, 2009, 88:2244–2252.
The Patented Aegis Vaccine TechnologyImmune Potentiation + Conserved Antigens
CONFIDENTIAL
HMGB1 is a highly conservedubiquitous protein, present in bothcellular nuclei and cytoplasm.
• Secreted by key immune cellse.g., macrophages and dendritic cells,in response to infection and damage.
• Binds and signals through TLR4 andRAGE, producing cytokines,e.g. TNF, IL-1α/β, inducing signalingcascades that mediate inflammationand innate immunity.
• Proposed as a potential vaccineadjuvant, capable of enhancingadaptive effector and memoryimmune responses. 1
Source: 1. Nature Reviews Immunology 5, 331-342 (2005)
Scientific Basis for Immune Potentiation with HMGB1
15
CONFIDENTIAL
CD40L (CD154) is expressed on activatedT cells and is a member of the TNFsuperfamily.
CD40 is expressed by B cells, macrophages,dendritic cells, monocytes, mast cells,fibroblasts, and endothelial cells.
CD40/CD40L-mediated signals activate antigenpresenting cells, induce and regulate thegeneration of T cell-dependent and humoralimmune responses.
Cognate B-cell/T-cell interactions are critical forsuccessful immunization, resulting in enhancedimmune responses, pro-inflammatory cytokineexpression, immunoglobulin class switching,(e.g., from IgG to IgA) and the induction ofimmunological memory. Source: Nature Immunology 8, 391-397 (2008)
Scientific Basis for Immune Potentiation with CD40L
16
Mannosylated Chitosan:• Binds to both antigens, and mannose receptors (CD206) on the surface of Antigen
Presenting Cells (APCs) - naturally adjuvates responses• Particularly important in inducing mucosal / IgA secretory immunity
Hercules is a universal carrier delivering selected antigens to the Antigen Presenting Cells of the immune system
Antigen
MannosylatedChitosan
APC (Dendritic Cell / Macrophages)
C O N F I D E N T I A L
Hercules is “sticky” – it passively adheres to mucous membranes and Antigen Presenting Cells in the mucous membranes
The Hercules Adjuvant / Delivery System Technology
17
Javelin is designed to induce fast, robust + long-lived specific IgG and IgA responses
CD40 is expressed on antigen presenting cells (APCs) and is required for true activation. Induces innate (TNF) expression and binds T&B cells – expansion and replication Administration of specific antigens with CD40 targets APCs in the mucosa-associated
lymphoid tissue (MALT) and enhances systemic specific IgG + IgA(s) responses
C O N F I D E N T I A L
Javelin is guided to target by an antibody – it actively adheres to CD40 on Antigen Presenting Cells
APC + CD40
CD40 antibody
Antibody
Antigen
Javelin complex binds antibody to CD40 on APC and antibody to vaccine antigen (e.g. influenza virus)
The Javelin Adjuvant / Delivery System Technology
18
CONFIDENTIAL
Appendix 2: Data Summaries
CONFIDENTIAL 20
Food Safety/Enteric Disease Vaccine
• A significant public health concern worldwide
• Human salmonellosis associated with the consumption of contaminated foods, such as fresh and processed meat and poultry, eggs, and fresh produce.
• According to USDA ERS, foodborne illness costs the US economy US$6.9 billion a year, of which Salmonella costs US$3.7 billion, E. coli O157 at US$478 million and Campylobacter at US$1.9 billion
Trial Achievements
PGT Salmonella vaccine demonstrated significant reduction after challenge with Salmonella Typhimurium.
PGT Salmonella vaccine demonstrated cross-protection against S Typhimurium, Heidelberg, Kentucky, Enteritidis(the most common food-borne illness serotypes of Salmonella)
Salmonella vaccine is also cross-protective against E. coli
PGT Technology• Different vectors of choice: Bacillus, Salmonella
(inactivated and live)• Expresses PAL, CJ0113, HMBGI as a fusion protein on the
surface cell vector• CJ0113 is a Campylobacter antigen and our ultimate aim
to market a combined broad spectrum Salmonella and Campylobacter vaccine for the food safety market
C O N F I D E N T I A L 21
Effect of live vaccination with the PGT Aegis vaccine on Salmonella Enteritidis recovery from ceca 10 days post challenge
PGT Aegis vaccine (live) against Salmonella Enteritidis
PGT Aegis vaccine (killed) against Salmonella Heidelberg
Effect of vaccination with killed PGT Aegis vaccine on Salmonella Heidelberg recovery from ceca 10 days post challenge
PGT live and killed vaccines demonstrate significant cross-protection across different Salmonella strains
Analysis of Vaccine Protection against E. coli with Hercules adjuvated recombinant killed vaccine (AFRIMS, Thailand)
0
10
20
30
40
50
60
70
80
90
100
Ileum Colon Cecum
Per
cen
t re
cove
ry E
TEC
Control
1 dose
2 doses
*P<0.05
*Significantly different (P<0.05) than Control
Cross-protection in E. coliHercules-adjuvated PGT oral Salmonella vaccine is protective in mice against E. coli
C O N F I D E N T I A L22
CONFIDENTIAL 23
Eimeria Vaccine
• Coccidiosis is a common disease caused by Eimeria parasites occurring in the digestive tract of poultry.
• Worldwide poultry losses due to coccidiosis are estimated to be between US$750 million and more than US$1.5 billion per year.
• Coccidiosis vaccines are among the most expensive vaccines in poultry production. No innovations in this market have occurred since the introduction of live oocyst vaccines in the 1960s.
• Current LIVE Eimeria vaccines are difficult to use and not popular with farmers
Trial Achievements
PGT Eimeria vaccine demonstrated cross protection against 5 economically important species of this parasite
PGT Eimeria vaccine radically reduced mortality post Eimeria maxima challenge
PGT Eimeria vaccine provided higher Body Weight (BW) and Body Weight Gain (BWG) of chicks post Eimeriamaxima challenge
PGT Technology• Orally administered bacillus vectored inactivated stand
alone vaccine in development• Expresses MPP, TRAP, HMBGI as a fusion protein on the
vector surface• The successful introduction of novel and effective PGT
vaccines against coccidiosis and necrotic enteritis will be a major advance for the poultry industry and the first such event in Eimeria and Clostridium perfringens control in decades
The Study
Vectored vaccines MPP HMGB1 and
TRAP MPP HMGB1 were tested for
ability to provide protection against
an Eimeria maxima challenge when
administered through the drinking
water in conjunction with a modified
chitosan adjuvant.
Broiler chicks were vaccinated at 4
and 14 days of age with the
respective vaccine in the drinking
water and challenged at day 21.
C O N F I D E N T I A L
*Significantly different (P<0.05) than Control
A B
PGT oral Eimeria vaccine candidates A + B adjuvated with Hercules radically reduce mortality by Eimeria maxima
24
CONFIDENTIAL
Vaccine Challenge
Strain Vaccine dose
Primary site
for lesion
scores
Oocyst Vaccine + PGT
Recombinant Vaccine
Oocysts w/o
PGT Vac
Oocysts +
PGT Vac
Live Oocyte
Vaccine
E. brunetti 40Large
Intestine Failed Passed
E. maxima 10Jejunum &
Ileum Failed Passed
E. necatrix 50 Jejunum Failed Passed
E. acervulina 150 Duodenum Passed Passed
E. tenella 25 Cecum Passed Passed
• 5 treatment groups, a vaccinated group (Group 1), a vaccinated group in combination with a low level of PGT’s Eimeria vaccine (Group 2), another vaccinated group in combination with a high level of PGT vaccine (Group 3), an unvaccinated positive control group (Group 4), and an unvaccinated unchallenged negative control group (Group 5).
• Groups 1 through 4 were challenged at 22 days of age and necropsied at 27 through 29 days of age. The primary response variable for establishing minimum protective dose was post-challenge intestinal lesion scores in the duodenum, jejunum, ileum, ceca, or large intestine depending on the primary replication site of each Eimeria species.
PGT’s Eimeria vaccine is cross-protective against 5 major species of Eimeria
Eimeria Vaccine: Cross-protection
25
CONFIDENTIAL 26
Toxoplasma gondii Vaccine
• Toxoplasma gondii, an economically important Apicomplexan parasite, causes abortion in sheep and presents a threat to humans, particularly pregnant women.
• Most mammals including humans can become infected with T. gondii (est. 23% in the US). Toxoplasmosis can develop in 'high risk' groups of individuals whose immunity is impaired, Congenital infection occurs in about 400-4,000 babies each year (result in retinal scars in both eyes, and permanent vision damage or blindness).
• Cats are the only mammal in which it reproduces, multiplies, and is shed back into the environment.
• No vaccine for cats currently on the market.
Trial Achievements
PGT Eimeria vaccine demonstrated cross protection against a similar parasite, T. gondii
Provided 80% protection after challenge in a pilot/proof of concept study
PGT Technology
• Orally administered bacillus vectored inactivated Eimeria stand alone vaccine
0
2
4
6
8
10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
CULMULATIVE MORTALITY
Group 1 Group 2 Group 3 Group 4 Group 5
G 5 (unvaccinated, unchallenged) no mortality.
G 4 (no vaccine, challenged) 100% mortality.
G 1 (oral high dose) 50% survival.
G 2 (oral low dose) and G 3 (peritoneal injection) 80% survival, significantly higher (P<0.05) than G 4.
C O N F I D E N T I A L 27
Cross-protection of Eimeria vaccine against Toxoplasma gondiiPGT killed Eimeria vaccine adjuvated with Hercules radically reduces mortality by T. gondii
Significant Results to Date
1. Superior immune response compared with
other adjuvants with minimal injection site
reaction.
Parenteral study of Hercules + inactivated
vaccine
2. Significant immune response observed via
oral administration including in drinking
water in animal studies with Hercules +
inactivated vaccines.
Key significance of oral administration:
parenteral injection is very labor intensive
to animals , esp. poultry
3. Successful POC challenge studies
conducted with Hercules + inactive
vectors.
Study conducted with MNC licensee
Hercules AdjuvantSignificant Results and Opportunities of Interest
Veterinary Markets of Interest *
Farm Animals
Aquaculture
Companion Animals
• Not in order of priority• Markets where Hercules has been tested or
currently being tested in various vaccines
C O N F I D E N T I A L28
* = p < 0.05
0
10
20
30
40
50
60
70
80
90
100
Control Chitosan Chitosan + CTB Chitosan +Saponin
MannosylatedChitosan
Pe
rce
nt
Re
cove
ry o
f Sa
lmo
ne
lla
Liver/Spleen
* *
*
Salmonella Recovery Liver/Spleen (L/S) or Cecal Tonsil (CT) on Day 22
(3 days following challenge)
*
S. Enteritidis challenge
on d19
S. Enteritidis recovery
on d22
• Serum IgG
• GIT mucosal IgA
The Study
Addition of Hercules yields zero percent recovery of Salmonella in the liver/spleen and
the lowest percent recovery in the cecal tonsil when compared with other adjuvants.
Comparison of Salmonella recovery following challenge with various adjuvants
C O N F I D E N T I A L29
Immune response to vaccination against swine influenza virus (iSIV)
The Study
One week after challenge, the IM/Oral/X combination resulted in the highest HI titers.
0
10
20
30
40
50
60
70
Bleed 1 Bleed 2 Bleed 3 Bleed 4 Bleed 5 (7 days postchallenge)
IM-ORAL-X
IM-X-ORAL
X-X-ORAL
No vaccine-CONTROLS
3 dose combinations: X = no vaccination
HI T
iter
Challenge isolate Heterologous H1N1Combinations of vaccination at weaning, 2 weeks post wean and 4 weeks post wean
Vaccinated -IM Vaccinated - ORAL Challenged with Heterologous Flu 1 wk post challenge
Bleed 1 (at weaning) Bleed 2 (2wks post wean) Bleed 3 (4wks post wean) Bleed 4 (6wks post wean) Bleed 5 (1wk post challenge)
Combinations of vaccination for an oral H1N1 vaccine and Hercules against swine flu in pigs
C O N F I D E N T I A L30
0
10
20
30
40
50
60
70
80
90
100
Ileum Colon Cecum
Per
cen
t re
cove
ry E
TEC
Oral ETEC Challenge without Hercules
Control
1 dose
2 doses
Killed Bacillus-vectored Salmonella Aegis vaccine against ETEC E. coli in a Mouse Model (AFRIMS)
Analysis of 2 dose Aegis Vaccine Protection against ETEC with
Hercules adjuvated and non-adjuvated recombinant killed vaccine
0
20
40
60
80
100
Ileum Colon CecumP
erce
nt
reco
very
ETE
C
Oral ETEC Challenge with Hercules
Control
1 dose
2 doses
**
*P<0.05
*
There is a clear demonstration that the Hercules-adjuvated (vs the non-adjuvated) PGT construct has an
immuno-protective effect in mice against ETEC challenge as evidenced by statistically significant
reduction of ETEC in the gut after an oral challenge.
*Significantly different (P<0.05) than Control
CONFIDENTIAL31
CONFIDENTIAL
1. Vaccination of chickens with recombinant Salmonella-expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. 2009, Poultry Science, 88 : 2244 – 2252
2. Evaluation of recombinant Salmonella expressing CD154 for persistence and enhanced antibody response in commercial turkeys. 2010, Poultry Science, 89 : 1399 – 1405
3. Development and evaluation of an ΔaroA / ΔhtrA Salmonella Enteritidis vector expressing Eimeria maxima TRAP family protein Em TFP250 with CD154 (CD40L) as candidate vaccines against coccidiosis in broilers. International Journal of Poultry Science, 9(11) : 1031-1037, 2010
4. Evaluation of Salmonella peptide epitopes for reduction of C. jejuni in broiler chickens. Clinical and Vaccine Immunology, March 2011, p449 – 454
1. Scarless and site-directed mutagenesis in Salmonella Enteritidis chromosome. BMC Biotechnology, 2007, 7 : 59
Key PGT Publications
32
Pacific GeneTech Limited17/F China Hong Kong Tower
8-12 Hennessy RoadHong Kong
Tel: +852-2525-8151web: www.pacificgenetech.com
contact: ctsang@pacificgenetech.com
Contact Us
CONFIDENTIAL